Company Description
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally.
The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.
It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation.
The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017.
InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.
| Country | Israel |
| Founded | 2008 |
| IPO Date | Aug 8, 2019 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 581 |
| CEO | Moshe Mizrahy |
Contact Details
Address: Tavor Building, Sha?ar Yokneam, Pob 533 Yokneam, L3 2069200 Israel | |
| Phone | 972-4-9097470 |
| Website | inmodemd.com |
Stock Details
| Ticker Symbol | INMD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $14.00 |
| CIK Code | 0001742692 |
| CUSIP Number | M5425M103 |
| ISIN Number | IL0011595993 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Yair Malca | Chief Financial Officer |
| Nava Tal-Launer | Chief Information Officer |
| Shakil Lakhani | President of North America |
| Moshe Mizrahy | Chairman and Chief Executive Officer |
| Alon Yaari | Vice President of Operations |
| Dr. Michael Kreindel | Chief Technology Officer and Director |
| Dr. Spero Theodorou M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 4, 2024 | 6-K | Report of foreign issuer |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | 6-K | Report of foreign issuer |
| Feb 13, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Feb 13, 2024 | 6-K | Report of foreign issuer |
| Feb 6, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 2, 2023 | 6-K | Report of foreign issuer |
| Aug 1, 2023 | 144 | Filing |
| Jul 27, 2023 | 6-K | Report of foreign issuer |